OCGN Stock Forecast 2023

Latest OCGN Price

MetricValueTrend
Current Market Cap$102.4 MLower
Trading Volume$744.1 KLower

Ocugen, Inc. (OCGN) is a clinical-stage biopharmaceutical company focused on developing and commercializing gene-based medicines, vaccines, and other biologic products. The company was founded in 2001 and is headquartered in Durham, North Carolina. Ocugen’s stock is listed on the Nasdaq Stock Exchange under the ticker symbol “OCGN.” The company’s stock was first listed on the Nasdaq on February 1, 2016.

OCGN Latest News

  • Ocugen CEO Confident in FDA Approval for Covaxin.¬†Ocugen CEO Bharath Srinivasan said in an interview that he is confident that the FDA will approve Covaxin. He said that the data from the Phase 3 trial is strong and that the advisory committee will likely recommend approval.

OCGN Stock Forecast 2023

The average OCGN Stock Forecast for the next 12 Months is $4

Average OCGN Stock Forecast for the next 12 Months$4
Chardan Capital$5
HC Wainwright & Co.$4
Mizuho$3

ReadXRP Price Prediction and Forecast

MetricTrend
Social MentionsSteady
UTC: Sep 25th, 2023 05:51 PM
Overall OutlookBearish
1. Market's WisdomBearish
1a. Market DataBearish
1b. Technical RecommendationSell
2. Crowd's WisdomNeutral
2a. Social Media BuzzSteady
2b. Social Media SentimentN/A

OGCN Price Prediction 2023

The price of OCGN stock in 2023 is difficult to predict. However, some analysts believe that the stock could reach $5 or even $10 if Covaxin is approved by the FDA. Others believe that the stock could be more volatile, and that it could fall if there are manufacturing delays or if Covaxin is not as effective as other COVID-19 vaccines.

Here are some of the factors that could impact OCGN’s stock price in 2023:

  • FDA approval for Covaxin: If Covaxin is approved by the FDA, it is likely that OCGN’s stock price will go up. The company could also receive additional revenue from the sale of Covaxin.
  • Manufacturing delays: If there are manufacturing delays for Covaxin, it could hurt OCGN’s stock price. The company could also face financial losses if it is unable to deliver Covaxin to customers on time.
  • Competition from other COVID-19 vaccines: There are other COVID-19 vaccines on the market, such as Pfizer’s Comirnaty and Moderna’s Spikevax. If these vaccines are more effective or have fewer side effects than Covaxin, it could hurt OCGN’s stock price.

Note: Crowdwisdom360 collates Predictions and data from all over the net and has no in-house view on the likely trends in the Stocks or Crypto Coins. Please consult a registered investment advisor to guide you on your financial decision

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.